No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
Top Premarket Decliners
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $23
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $32
Express News | Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025